Primary Immune Thrombocytopenia (ITP) Clinical Trials

10 recruiting

Primary Immune Thrombocytopenia (ITP) Trials at a Glance

12 actively recruiting trials for primary immune thrombocytopenia (itp) are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 3 with 6 trials, with the heaviest enrollment activity in Tianjin, Nanchang, and Greenville. Lead sponsors running primary immune thrombocytopenia (itp) studies include Institute of Hematology & Blood Diseases Hospital, China, Chongqing Peg-Bio Biopharm Co., Ltd., and Beijing InnoCare Pharma Tech Co., Ltd..

Browse primary immune thrombocytopenia (itp) trials by phase

Treatments under study

About Primary Immune Thrombocytopenia (ITP) Clinical Trials

Looking for clinical trials for Primary Immune Thrombocytopenia (ITP)? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Primary Immune Thrombocytopenia (ITP) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Primary Immune Thrombocytopenia (ITP) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
argenx69 enrolled94 locationsNCT06544499
Recruiting
Phase 4

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China224 enrolled1 locationNCT04518475
Recruiting
Phase 3

High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Shandong University86 enrolled1 locationNCT07559331
Recruiting
Phase 3

An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Grand Shuyang Life Sciences (Chengdu) Co., Ltd.36 enrolled9 locationsNCT07233213
Recruiting
Phase 3

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

Chronic Primary Immune Thrombocytopenia (ITP)
Kedrion S.p.A.40 enrolled27 locationsNCT07059000
Recruiting
Phase 1

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)
Chongqing Peg-Bio Biopharm Co., Ltd.12 enrolled5 locationsNCT06880081
Recruiting
Phase 1Phase 2

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)
Jiangsu BioJeTay Biotechnology Co., Ltd.56 enrolled7 locationsNCT06929299
Recruiting
Early Phase 1

Safety Study of CC312 in Autoimmune Disease Patients

Rheumatoid Arthritis (RA)Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus (SLE)+3 more
CytoCares Inc18 enrolled1 locationNCT06888960
Recruiting
Phase 2

Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial

Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China129 enrolled1 locationNCT06992128
Recruiting

RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)ITP - Immune Thrombocytopenia
Fundación Española de Hematología y Hemoterapía1,000 enrolled36 locationsNCT06919341
Recruiting
Phase 3

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Chronic Primary Immune Thrombocytopenia (ITP)
Beijing InnoCare Pharma Tech Co., Ltd.195 enrolled45 locationsNCT06004856
Recruiting
Phase 3

Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Assistance Publique - Hôpitaux de Paris132 enrolled1 locationNCT05338190